Nanomedicine for the cardiac myocyte: Where are we?

Journal of Controlled Release

Volumn 271, Issue , 2018, Pages 149-165

  Lozano, Omar ^a,b   Torres Quintanilla, Alejandro ^a   García Rivas, Gerardo ^a,b  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

^b HOSPITAL ZAMBRANO HELLION   (Mexico)

Author keywords

Active targeting; Cardiac myocyte; Drug delivery; Heart on a chip; Imaging; Nanomedicine; Nanosafety; Scaffolds; Tissue engineering

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; DRUG DELIVERY; HEART; IMAGING TECHNIQUES; MEDICAL NANOTECHNOLOGY; SCAFFOLDS; SCAFFOLDS (BIOLOGY); TISSUE; TISSUE ENGINEERING;

ACTIVE TARGETING; CARDIAC MYOCYTES; NANOSAFETY; SUSTAINED RELEASE; THERAPEUTIC INTERVENTION; THERAPY DELIVERY; TISSUE REPAIR; TISSUE TARGETING;

TARGETED DRUG DELIVERY;

NANOMATERIAL;

APOPTOSIS; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL SELECTION; CHRONIC DISEASE; EXTRACELLULAR MATRIX; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; TISSUE ENGINEERING; TISSUE REPAIR; ANIMAL; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MYOCYTES, CARDIAC; NANOMEDICINE; NANOSTRUCTURES;

EID: 85040680152     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.12.018     Document Type: Review

References (158)

1. Murray, C. et al., Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 385:9963 (2014), 117–171.
2. Yacoub, M., Suzuki, K., Rosenthal, N., The future of regenerative therapy in patients with chronic heart failure. Nat. Clin. Pract. Cardiovasc. Med. 3:Suppl. 1 (2006), S133–S135.
3. Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotech. 33:9 (2015), 941–951.
4. Shi, D. et al., Photo-fluorescent and magnetic properties of iron oxide nanoparticles for biomedical applications. Nano 7:18 (2015), 8209–8232.
5. Dvir, T. et al., Nanowired three-dimensional cardiac patches. Nat. Nanotechnol. 6:11 (2011), 720–725.
6. Zhang, Y.S. et al., From cardiac tissue engineering to heart-on-a-chip: beating challenges. Biomed. Mater., 10(3), 2015, 034006.
7. EC, Commission Recommendation of 18 October 2011 on the definition of nanomaterial. E. Commission, (eds.) 2011/696/EU, vol. 275, 2011, 38–40.
8. Oberdörster, G., Stone, V., Donaldson, K., Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1:1 (2007), 2–25.
9. Escamilla-Rivera, V. et al., Protein corona acts as a protective shield against Fe3O4-PEG inflammation and ROS-induced toxicity in human macrophages. Toxicol. Lett. 240:1 (2016), 172–184.
10. Lozano, O. et al., Effects of SiC nanoparticles orally administered in a rat model: biodistribution, toxicity and elemental composition changes in feces and organs. Toxicol. Appl. Pharmacol. 264:2 (2012), 232–245.
11. Lozano, O. et al., Development of a PIXE analysis method for the determination of the biopersistence of SiC and TiC nanoparticles in rat lungs. Nanotoxicology 6:3 (2012), 263–271.
12. Gentemann, L. et al., Modulation of cardiomyocyte activity using pulsed laser irradiated gold nanoparticles. Biomed. Opt. Express 8:1 (2017), 177–192.
13. Dvir, T. et al., Nanoparticles targeting the infarcted heart. Nano Lett. 11:10 (2011), 4411–4414.
14. Verma, D.D. et al., ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J. Drug Target. 14:5 (2006), 273–280.
15. Savi, M. et al., Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. Part Fibre Toxicol., 11, 2014, 63.
16. Verma, V.K. et al., Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging. Int. J. Nanomedicine 10 (2015), 711–726.
17. Maxwell, J.T. et al., Bioactive nanoparticles improve calcium handling in failing cardiac myocytes. Nanomedicine 10:22 (2015), 3343–3357.
18. Shin, S.R. et al., Carbon-nanotube-embedded hydrogel sheets for engineering cardiac constructs and bioactuators. ACS Nano 7:3 (2013), 2369–2380.
19. Cheng, K. et al., Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun., 5, 2014, 4880.
20. Pagliari, F. et al., Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. ACS Nano 6:5 (2012), 3767–3775.
21. Mohrman, D., Heller, L., Cardiovascular Physiology. Seventh Edition, 2010, McGraw Hill Professional.
22. de J García-Rivas, G. et al., Ru(360), a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br. J. Pharmacol. 149:7 (2006), 829–837.
23. Pogwizd, S.M. et al., Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ. Res. 88:11 (2001), 1159–1167.
24. Bers, D.M., Cardiac excitation-contraction coupling. Nature 415:6868 (2002), 198–205.
25. Garcia-Rivas, G.J., Torre-Amione, G., Abnormal mitochondrial function during ischemia reperfusion provides targets for pharmacological therapy. Methodist Debakey Cardiovasc. J. 5:3 (2009), 2–7.
26. Fuster, V. et al., Hurst's the Heart. 14th Edition, 2017, McGraw Hill Professional.
27. Kolwicz, S.C. Jr., Purohit, S., Tian, R., Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ. Res. 113:5 (2013), 603–616.
28. Riojas-Hernandez, A. et al., Enhanced oxidative stress sensitizes the mitochondrial permeability transition pore to opening in heart from Zucker Fa/fa rats with type 2 diabetes. Life Sci. 141 (2015), 32–43.
29. Schaper, J., Meiser, E., Stammler, G., Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ. Res. 56:3 (1985), 377–391.
30. Junge, W., Nelson, N., ATP synthase. Annu. Rev. Biochem. 84 (2015), 631–657.
31. Silva-Platas, C. et al., Cardiotoxicity of acetogenins from Persea Americana occurs through the mitochondrial permeability transition pore and caspase-dependent apoptosis pathways. J. Bioenerg. Biomembr. 44:4 (2012), 461–471.
32. Silva-Platas, C. et al., Antineoplastic copper coordinated complexes (Casiopeinas) uncouple oxidative phosphorylation and induce mitochondrial permeability transition in cardiac mitochondria and cardiomyocytes. J. Bioenerg. Biomembr. 48:1 (2016), 43–54.
33. Fernández-Sada, E. et al., Cardiac responses to β-adrenoceptor stimulation is partly dependent on mitochondrial calcium uniporter activity. Br. J. Pharmacol. 171:18 (2014), 4207–4221.
34. Grech, E.D., Pathophysiology and investigation of coronary artery disease. BMJ 326:7397 (2003), 1027–1030.
35. Libby, P., Theroux, P., Pathophysiology of coronary artery disease. Circulation 111:25 (2005), 3481–3488.
36. Crossman, D.C., The pathophysiology of myocardial ischaemia. Heart 90:5 (2004), 576–580.
37. Detry, J.M., The pathophysiology of myocardial ischaemia. Eur. Heart J. 17:Suppl G (1996), 48–52.
38. Ibanez, B. et al., Evolving therapies for myocardial ischemia/reperfusion injury. J. Am. Coll. Cardiol. 65:14 (2015), 1454–1471.
39. Heusch, G., Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381:9861 (2013), 166–175.
40. Michiels, C., Physiological and pathological responses to hypoxia. Am. J. Pathol. 164:6 (2004), 1875–1882.
41. Kalogeris, T. et al., Cell biology of ischemia/reperfusion injury. Int. Rev. Cell Mol. Biol. 298 (2012), 229–317.
42. Parra, E. et al., Myocardial protective effect of octylguanidine against the damage induced by ischemia reperfusion in rat heart. Mol. Cell. Biochem. 269:1 (2005), 19–26.
43. Halestrap, A.P., A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem. Soc. Trans. 38:4 (2010), 841–860.
44. Yellon, D.M., Hausenloy Myocardial, D.J., Reperfusion injury. N. Engl. J. Med. 357:11 (2007), 1121–1135.
45. Konstantinidis, K., Whelan, R.S., Kitsis, R.N., Mechanisms of cell death in heart disease. Arterioscler. Thromb. Vasc. Biol. 32:7 (2012), 1552–1562.
46. Braunwald, E., Kloner, R.A., Myocardial reperfusion: a double-edged sword?. J. Clin. Invest. 76:5 (1985), 1713–1719.
47. Ibanez, B. et al., Lethal myocardial reperfusion injury: a necessary evil?. Int. J. Cardiol. 151:1 (2011), 3–11.
48. de Jesus Garcia-Rivas, G. et al., Inhibition of the mitochondrial calcium uniporter by the oxo-bridged dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in postischemic rat heart. FEBS J. 272:13 (2005), 3477–3488.
49. Sanada, S., Komuro, I., Kitakaze, M., Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am. J. Physiol. Heart Circ. Physiol. 301:5 (2011), H1723–41.
50. Raedschelders, K., Ansley, D.M., Chen, D.D., The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol. Ther. 133:2 (2012), 230–255.
51. Arbustini, E. et al., Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am. J. Pathol. 153:5 (1998), 1501–1510.
52. Wai, T. et al., Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science, 350(6265), 2015 (aad0116).
53. Graham, B.H. et al., A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat. Genet. 16:3 (1997), 226–234.
54. Peter, A.K., Bjerke, M.A., Leinwand, L.A., Biology of the cardiac myocyte in heart disease. Mol. Biol. Cell 27:14 (2016), 2149–2160.
55. Treviño-Saldaña, N., García-Rivas, G., Regulation of sirtuin-mediated protein deacetylation by cardioprotective phytochemicals. Oxidative Med. Cell. Longev., 2017, 2017, 1750316 https://www.hindawi.com/journals/omcl/2017/1750306/cta/ (Article ID 1750306).
56. Diaz, R.J., Wilson, G.J., Studying ischemic preconditioning in isolated cardiomyocyte models. Cardiovasc. Res. 70:2 (2006), 286–296.
57. Lynch, I., Salvati, A., Dawson, K.A., Protein-nanoparticle interactions: what does the cell see?. Nat. Nanotechnol. 4:9 (2009), 546–547.
58. Monopoli, M.P. et al., Physical − chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133:8 (2011), 2525–2534.
59. Salvati, A. et al., Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8:2 (2013), 137–143.
60. Jokerst, J.V. et al., Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 6:4 (2011), 715–728.
61. Knop, K. et al., Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49:36 (2010), 6288–6308.
62. Parodi, A. et al., Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8:1 (2013), 61–68.
63. Hu, C.M. et al., Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U. S. A. 108:27 (2011), 10980–10985.
64. Arvizo, R.R. et al., Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One, 6(9), 2011, e24374.
65. Hirn, S. et al., Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm. 77:3 (2011), 407–416.
66. Schleh, C. et al., Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 6:1 (2012), 36–46.
67. Hossain, S.S. et al., In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine (Lond.) 8:3 (2013), 343–357.
68. Gentile, F. et al., The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 41:10 (2008), 2312–2318.
69. Suarez, S., Almutairi, A., Christman, K.L., Micro- and nanoparticles for treating cardiovascular disease. Biomater. Sci. 3:4 (2015), 564–580.
70. Ruiz-Esparza, G.U. et al., The physiology of cardiovascular disease and innovative liposomal platforms for therapy. Int. J. Nanomedicine 8 (2013), 629–640.
71. Kim, J. et al., Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 11:2 (2011), 694–700.
72. Garcia-Rivas, G. et al., Standardized extracts from black bean coats (Phaseolus vulgaris L.) prevent adverse cardiac remodeling in a murine model of non-ischemic cardiomyopathy. RSC Adv. 5:110 (2015), 90858–90865.
73. Ruiz-Esparza, G.U. et al., A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur. J. Heart Fail. 18:2 (2016), 169–178.
74. Segura-Ibarra, V. et al., Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. Int. J. Pharm. 524:1–2 (2017), 257–267.
75. Le Roy, C., Wrana, J.L., Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat. Rev. Mol. Cell Biol. 6:2 (2005), 112–126.
76. Miller, C.R. et al., Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37:37 (1998), 12875–12883.
77. Serda, R.E. et al., The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials 30:13 (2009), 2440–2448.
78. Miragoli, M. et al., Functional interaction between charged nanoparticles and cardiac tissue: a new paradigm for cardiac arrhythmia?. Nanomedicine (Lond.) 8:5 (2013), 725–737.
79. Ferreira, M.P. et al., In vitro and in vivo assessment of heart-homing porous silicon nanoparticles. Biomaterials 94 (2016), 93–104.
80. Ornelas, N. et al., Enhancing internalization of silica particles in myocardial cells through surface modification. Mater. Sci. Eng. C 79 (October 1 2017), 831–840 http://www.sciencedirect.com/science/article/pii/S0928493116324651.
81. Gould, G.W., Lippincott-Schwartz, J., New roles for endosomes: from vesicular carriers to multi-purpose platforms. Nat. Rev. Mol. Cell Biol. 10:4 (2009), 287–292.
82. Marsh, M., Endocytosis. 2001, Oxford University Press.
83. Chou, L.Y.T., Ming, K., Chan, W.C.W., Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40:1 (2011), 233–245.
84. Martens, T.F. et al., Intracellular delivery of nanomaterials: how to catch endosomal escape in the act. Nano Today 9:3 (2014), 344–364.
85. Zhu, K. et al., Nanovector-based prolyl hydroxylase domain 2 silencing system enhances the efficiency of stem cell transplantation for infarcted myocardium repair. Int. J. Nanomedicine 9 (2014), 5203–5215.
86. Gradishar, W.J., Albumin-bound paclitaxel: a next-generation taxane. Expert. Opin. Pharmacother. 7:8 (2006), 1041–1053.
87. Di Mauro, V. et al., Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine (Lond.) 11:8 (2016), 891–906.
88. Laloy, J. et al., Can TiC nanoparticles produce toxicity in oral administration to rats?. Toxicol. Rep. 1 (2014), 172–187.
89. Lozano, O. et al., How does the deposited dose of oxide nanomaterials evolve in an in vitro assay?. J. Phys. Conf. Ser., 429(1), 2013, 012013.
90. Relier, C. et al., Study of TiO2 P25 nanoparticles genotoxicity on lung, blood and liver cells in lung overload and non-overload conditions after repeated respiratory exposure in rats. Toxicol. Sci. 156:2 (Apr 1 2017), 527–537, 10.1093/toxsci/kfx006 https://www.ncbi.nlm.nih.gov/pubmed/28087835.
91. Guerrero-Beltrán, C. et al., Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca2+ handling in adult rat cardiomyocytes. Am. J. Phys. Heart Circ. Phys. 312:4 (Apr 1 2017), H645–H661, 10.1152/ajpheart.00564.2016 https://www.ncbi.nlm.nih.gov/pubmed/28130337.
92. Du, Z.-J. et al., Inhibition of gap junction intercellular communication is involved in silica nanoparticles-induced H9c2 cardiomyocytes apoptosis via the mitochondrial pathway. Int. J. Nanomedicine 12 (2017), 2179–2188.
93. Duan, J. et al., Low-dose exposure of silica nanoparticles induces cardiac dysfunction via neutrophil-mediated inflammation and cardiac contraction in zebrafish embryos. Nanotoxicology 10:5 (2016), 575–585.
94. Ramirez-Lee Manuel, A. et al., Evaluation of vascular tone and cardiac contractility in response to silver nanoparticles, using Langendorff rat heart preparation. Nanomedicine 13:4 (2017), 1507–1518.
95. Korani, M., Rezayat, S.M., Arbabi Bidgoli, S., Sub-chronic dermal toxicity of silver nanoparticles in Guinea pig: special emphasis to heart, bone and kidney toxicities. Iran J. Pharm. Res. 12:3 (2013), 511–519.
96. Yu, X., Hong, F., Zhang, Y.Q., Cardiac inflammation involving in PKCepsilon or ERK1/2-activated NF-kappaB signalling pathway in mice following exposure to titanium dioxide nanoparticles. J. Hazard. Mater. 313 (2016), 68–77.
97. Hathaway, Q.A. et al., Maternal-engineered nanomaterial exposure disrupts progeny cardiac function and bioenergetics. Am. J. Physiol. Heart Circ. Physiol. 312:3 (2017), H446–H458.
98. Contreras-Torres, F.F. et al., Differential cytotoxicity and internalization of graphene family nanomaterials in myocardial cells. Mater. Sci. Eng. C 73 (2017), 633–642.
99. Ikeda, G. et al., Nanoparticle-mediated targeting of cyclosporine a enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci. Rep., 6, 2016, 20467.
100. Psarros, C. et al., Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas 73:1 (2012), 52–60.
101. Bowey, K., Tanguay, J.F., Tabrizian, M., Liposome technology for cardiovascular disease treatment and diagnosis. Expert Opin. Drug Deliv. 9:2 (2012), 249–265.
102. Lukyanenko, V., Lukyanenko, Y., Oxysterols in heart failure. Futur. Cardiol. 5:4 (2009), 343–354.
103. Kahn, E. et al., Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells. Int. J. Nanomedicine 5 (2010), 185–195.
104. Kennedy, D.C. et al., Nanoscale aggregation of cellular beta2-adrenergic receptors measured by plasmonic interactions of functionalized nanoparticles. ACS Nano 3:8 (2009), 2329–2339.
105. Oropeza-Almazán, Y. et al., Small interfering RNA targeting mitochondrial calcium uniporter improves cardiomyocyte cell viability in hypoxia/reoxygenation injury by reducing calcium overload. Oxidative Med. Cell. Longev., 2017, 2017, 13.
106. Schubert, D. et al., Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun. 342:1 (2006), 86–91.
107. Celardo, I. et al., Pharmacological potential of cerium oxide nanoparticles. Nano 3:4 (2011), 1411–1420.
108. Niu, J. et al., Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc. Res. 73:3 (2007), 549–559.
109. Ahmed, S.M., Abdelrahman, S.A., Salama, A.E., Efficacy of gold nanoparticles against isoproterenol induced acute myocardial infarction in adult male albino rats. Ultrastruct. Pathol. 41:2 (2017), 168–185.
110. Ruiz-Meana, M., García-Dorado, D., Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Revista Española de Cardiología (English Edition) 62:2 (2009), 199–209.
111. Kuzmin, A.I. et al., Interstitial ATP level and degradation in control and postmyocardial infarcted rats. Am. J. Phys. 275:3 Pt 1 (1998), C766–71.
112. Duerr, R.L. et al., Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J. Clin. Invest. 95:2 (1995), 619–627.
113. Prêle, C.M. et al., Insulin-like growth factor-1 overexpression in cardiomyocytes diminishes ex vivo heart functional recovery after acute ischemia. Cardiovasc. Pathol. 21:1 (2012), 17–27.
114. Chang, M.Y. et al., Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Control. Release 170:2 (2013), 287–294.
115. Somasuntharam, I. et al., Knockdown of TNF-alpha by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction. Biomaterials 83 (2016), 12–22.
116. Liu, J. et al., Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials 34:14 (2013), 3729–3736.
117. Khudairi, T., Khaw, B.-A., Preservation of ischemic myocardial function and integrity with targeted cytoskeleton-specific immunoliposomes. J. Am. Coll. Cardiol. 43:9 (2004), 1683–1689.
118. Lee, K. et al., Peptide-enhanced mRNA transfection in cultured mouse cardiac fibroblasts and direct reprogramming towards cardiomyocyte-like cells. Int. J. Nanomedicine 10 (2015), 1841–1854.
119. Park, J. et al., Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair. ACS Nano 9:5 (2015), 4987–4999.
120. Lozano, O. et al., PT167 RU360 adsorption in silica nanovectors: potential use against mitochondrial dysfunction in heart failure. Glob. Heart, 11(2), 2016, e152.
121. Segura-Ibarra, V. et al., Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention. J. Control. Release 262 (Sep 28 2017), 18–27, 10.1016/j.jconrel.2017.07.012 https://www.ncbi.nlm.nih.gov/pubmed/28700900.
122. Zhao, Y.Z. et al., Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy. Int. J. Nanomedicine 11 (2016), 675–686.
123. Zhao, Y.Z. et al., Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. J. Control. Release 223 (2016), 11–21.
124. Boden, G., Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18:2 (2011), 139–143.
125. Li, J. et al., Relief of oxidative stress and cardiomyocyte apoptosis by using curcumin nanoparticles. Colloids Surf. B Biointerfaces 153 (2017), 174–182.
126. Zhuge, Y. et al., Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model. Int. J. Nanomedicine 11 (2016), 2359–2367.
127. Cuadrado, I. et al., EMMPRIN-targeted magnetic nanoparticles for in vivo visualization and regression of acute myocardial infarction. Theranostics 6:4 (2016), 545–557.
128. Kang, P.M., Izumo, S., Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol. Med. 9:4 (2003), 177–182.
129. Reutelingsperger, C.P.M. et al., Visualization of cell death in vivo with the annexin A5 imaging protocol. J. Immunol. Methods 265:1–2 (2002), 123–132.
130. Sosnovik, D.E. et al., Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54:3 (2005), 718–724.
131. Sosnovik, D.E. et al., Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Circ. Cardiovasc. Imaging 2:6 (2009), 460–467.
132. Sosnovik, D.E. et al., Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ. Cardiovasc. Imaging 2:6 (2009), 468–475.
133. You, J.-O. et al., Nanoengineering the heart: conductive scaffolds enhance connexin 43 expression. Nano Lett. 11:9 (2011), 3643–3648.
134. Engelmayr, G.C. et al., Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat. Mater. 7:12 (2008), 1003–1010.
135. Hsiao, C.W. et al., Electrical coupling of isolated cardiomyocyte clusters grown on aligned conductive nanofibrous meshes for their synchronized beating. Biomaterials 34:4 (2013), 1063–1072.
136. Kharaziha, M. et al., Tough and flexible CNT-polymeric hybrid scaffolds for engineering cardiac constructs. Biomaterials 35:26 (2014), 7346–7354.
137. Zhou, J. et al., Engineering the heart: evaluation of conductive nanomaterials for improving implant integration and cardiac function. Sci. Rep., 4, 2014, 3733.
138. Murtuza, B., Nichol, J.W., Khademhosseini, A., Micro- and nanoscale control of the cardiac stem cell niche for tissue fabrication. Tissue Eng. Part B Rev. 15:4 (2009), 443–454.
139. Ahadian, S. et al., Hybrid hydrogels containing vertically aligned carbon nanotubes with anisotropic electrical conductivity for muscle myofiber fabrication. Sci. Rep., 4, 2014, 4271.
140. Ramón-Azcón, J. et al., Dielectrophoretically aligned carbon nanotubes to control electrical and mechanical properties of hydrogels to fabricate contractile muscle myofibers. Adv. Mater. 25:29 (2013), 4028–4034.
141. Liu, Y. et al., Tuning the conductivity and inner structure of electrospun fibers to promote cardiomyocyte elongation and synchronous beating. Mater. Sci. Eng. C Mater. Biol. Appl. 69 (2016), 865–874.
142. Ahadian, S. et al., Hybrid hydrogel-aligned carbon nanotube scaffolds to enhance cardiac differentiation of embryoid bodies. Acta Biomater. 31 (2016), 134–143.
143. Asiri, A.M. et al., Greater cardiomyocyte density on aligned compared with random carbon nanofibers in polymer composites. Int. J. Nanomedicine 9 (2014), 5533–5539.
144. Asiri, A.M. et al., Understanding greater cardiomyocyte functions on aligned compared to random carbon nanofibers in PLGA. Int. J. Nanomedicine 10 (2015), 89–96.
145. Deng, S. et al., Neonatal heart-enriched miR-708 promotes proliferation and stress resistance of cardiomyocytes in rodents. Theranostics 7:7 (2017), 1953–1965.
146. Sun, H. et al., Carbon nanotubes enhance intercalated disc assembly in cardiac myocytes via the beta1-integrin-mediated signaling pathway. Biomaterials 55 (2015), 84–95.
147. Li, Y. et al., AuNP-collagen matrix with localized stiffness for cardiac-tissue engineering: enhancing the assembly of intercalated discs by beta1-integrin-mediated signaling. Adv. Mater. 28:46 (2016), 10230–10235.
148. Ogawa, Y., Kim, M.H., Kino-Oka, M., Migration-driven aggregate behaviors of human mesenchymal stem cells on a dendrimer-immobilized surface direct differentiation toward a cardiomyogenic fate commitment. J. Biosci. Bioeng. 122:5 (2016), 627–632.
149. Chiu, Y.W. et al., The arrhythmogenic effect of self-assembling nanopeptide hydrogel scaffolds on neonatal mouse cardiomyocytes. Nanomedicine 10:5 (2014), 1065–1073.
150. Tokunaga, M. et al., Implantation of cardiac progenitor cells using self-assembling peptide improves cardiac function after myocardial infarction. J. Mol. Cell. Cardiol. 49:6 (2010), 972–983.
151. Curtin, C.M. et al., Innovative collagen nano-hydroxyapatite scaffolds offer a highly efficient non-viral gene delivery platform for stem cell-mediated bone formation. Adv. Mater. 24:6 (2012), 749–754.
152. Paul, A. et al., Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano 8:8 (2014), 8050–8062.
153. Fang, R. et al., Sustained co-delivery of BIO and IGF-1 by a novel hybrid hydrogel system to stimulate endogenous cardiac repair in myocardial infarcted rat hearts. Int. J. Nanomedicine 10 (2015), 4691–4703.
154. Mandoli, C. et al., Stem cell aligned growth induced by CeO2 nanoparticles in PLGA scaffolds with improved bioactivity for regenerative medicine. Adv. Funct. Mater. 20:10 (2010), 1617–1624.
155. Kumar, A. et al., Thymosin beta4 coated nanofiber scaffolds for the repair of damaged cardiac tissue. J. Nanobiotechnol., 12, 2014, 10.
156. Annabi, N. et al., Hydrogel-coated microfluidic channels for cardiomyocyte culture. Lab Chip 13:18 (2013), 3569–3577.
157. Chen, M.B. et al., A 3D microfluidic platform incorporating methacrylated gelatin hydrogels to study physiological cardiovascular cell-cell interactions. Lab Chip 13:13 (2013), 2591–2598.
158. Zaretski, A.V. et al., Metallic nanoislands on graphene as highly sensitive transducers of mechanical, biological, and optical signals. Nano Lett. 16:2 (2016), 1375–1380.